LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Combination Rapid Diagnostic Tests Evaluated for Malaria in Pregnancy

By LabMedica International staff writers
Posted on 10 Nov 2015
Print article
Image: The CareStart Malaria pLDH/HRP2 combo rapid diagnostic test (Photo courtesy of Access Bio Inc.).
Image: The CareStart Malaria pLDH/HRP2 combo rapid diagnostic test (Photo courtesy of Access Bio Inc.).
Early detection and effective management of asymptomatic and symptomatic malaria is essential to reduce the burden of malaria in pregnancy.

The potential risk of Plasmodium falciparum or P. vivax malaria and the corresponding risk of malaria associated maternal anemia and low birth weight due to pre-term delivery or intra-uterine growth retardation needs to be urgently addressed.

An international team of scientists led by those at the Liverpool School of Tropical Medicine (UK) enrolled pregnant women of any gravidity aged between 15 and 49 years who attended clinics for routine antenatal care between March and July 2012. A finger prick blood sample was taken to simultaneously test the four rapid diagnostic tests (RDTs), malaria microscopy and dried blood spots for polymerase chain reaction (PCR).

Thick and thin smears were made on the same slide and stained with 5 % Giemsa. A slide was declared negative if parasites were absent after examining 200 high power fields. Parasite density was quantified against 300 leukocytes on an assumed leukocyte count of 8,000/µL of blood. The four HRP-2/pLDH RDTs included Parascreen Rapid Test Pan/Pf (Zephyr Biomedical System; Goa, India); SD Bioline Malaria Ag Pf/Pan (Standard Diagnostic Inc.; Suwon City, Republic of Korea); CareStart Malaria pLDH/HRP2 combo (Access Bio Inc.; Somerset, NJ, USA); the two RDTs used in the malaria control program in Indonesia at the time of the study, and First Response Malaria pLDH/HRP-2 combo (Premier Medical Corporation Ltd.; Kachigam, India). Nested PCR was performed on all samples to detect malaria parasites and for speciation.

Overall 950 women were recruited and 98.7% were asymptomatic. The prevalence of malaria was 3.0% to 3.4% by RDTs, and 3.6% by field microscopy, 5.0% by expert microscopy and 6.6% by PCR, The geometric-mean parasite density was low, P. falciparum = 418 parasites/µL, and P. vivax = 147/µL. Compared with PCR, the overall sensitivity of the RDTs and field microscopy to detect any species was 24.6% to 31.1%; specificities were greater than 98.4 %. Relative to PCR, the First-Response RDT had the best diagnostic accuracy for any species with the sensitivity = 31.1 %, and specificity = 98.9 %.

The authors concluded that the diagnostic accuracy to detect malaria among mostly asymptomatic pregnant women and perceived ease of use was slightly better with First-Response, but overall, differences between the four RDTs were small and performance comparable to field microscopy. Combination RDTs are a suitable alternative to field microscopy to screen for malaria in pregnancy in rural Indonesia. The clinical relevance of low density malaria infections detected by PCR, but undetected by RDTs or microscopy needs to be determined. The study was published on October 29, 2015, in the Malaria Journal.

Related Links:

Liverpool School of Tropical Medicine 
Zephyr Biomedical System 
Access Bio Inc. 



Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Coagulation Analyzer
CS-2400

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Sekisui Diagnostics UK Ltd.